Two main receptors have been recently investigated with regard to AA pathophysiology; while OR6A2 (Olfr2) is associated with vascular wall inflammation, atherosclerotic plaque size and AA progression, OR2L13 (Olfr168) is associated with prevention of platelet aggregation, and in experimental studies, deficiency in this receptor is associated with faster aneurysm progression and increased risk of rupture. Here, OR2H2 is linked to aneurysm.